Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Two Doses of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus

NCT02446912 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT02446912
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02446912 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Two Doses of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Completed
Start date
June 9, 2015
Completion date
July 17, 2018
Enrollment
460 (actual)
Sites
145

Conditions

As the registry lists them; a condition with its own page is linked.

active systemic lupus erythematosus